New surgical approaches for clinically high-risk or metastatic prostate cancer

Paolo Dell’Oglio, Armando Stabile, G Gandaglia, E Zaffuto, Nicola Fossati, M Bandini, N Suardi, PI Karakiewicz, SF Shariat, F Montorsi, A Briganti

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

© 2017 Informa UK Limited, trading as Taylor & Francis Group. Introduction: A considerable number of individuals with prostate cancer (PCa) still harbor locally-advanced and metastatic disease. Although such men were initially not considered eligible for local treatment, the role of radical prostatectomy (RP) has been recently reassessed. Areas covered: This review analyses currently published evidences regarding new surgical approaches for clinically high-risk PCa individuals, as well as the role of cytoreductive surgery in the metastatic setting. The role of robot-assisted radical prostatectomy (RARP) and extended pelvic lymph node dissection will be evaluated with regards to perioperative, oncologic, as well as functional outcomes. Expert commentary: RARP is a feasible approach in PCa patients regardless of the presence of high-risk disease features and can achieve optimal short-term oncologic outcomes and acceptable short/intermediate-term functional outcomes, that are comparable to those reported for open RP. Extended pelvic lymph node dissection can be performed in this setting and should be recommended for all high-risk PCa patients. The overall rate of complications in contemporary men treated with RARP for high-risk disease is not negligible. Cytoreduction in the oligo-metastatic setting is feasible and relatively safe, although evidence is scarce to recommend its widespread adoption. In consequence, longer follow-up data and, ideally, randomized controlled trials are needed. © 2017 Informa UK Limited, trading as Taylor & Francis Group.
Original languageEnglish
Pages (from-to)1013-1031
Number of pages19
JournalExpert Review of Anticancer Therapy
Volume17
Issue number11
DOIs
Publication statusPublished - 2017

Fingerprint

Prostatectomy
Prostatic Neoplasms
Lymph Node Excision
Randomized Controlled Trials
Therapeutics

Cite this

New surgical approaches for clinically high-risk or metastatic prostate cancer. / Dell’Oglio, Paolo; Stabile, Armando; Gandaglia, G; Zaffuto, E; Fossati, Nicola; Bandini, M; Suardi, N; Karakiewicz, PI; Shariat, SF; Montorsi, F; Briganti, A.

In: Expert Review of Anticancer Therapy, Vol. 17, No. 11, 2017, p. 1013-1031.

Research output: Contribution to journalArticle

Dell’Oglio, P, Stabile, A, Gandaglia, G, Zaffuto, E, Fossati, N, Bandini, M, Suardi, N, Karakiewicz, PI, Shariat, SF, Montorsi, F & Briganti, A 2017, 'New surgical approaches for clinically high-risk or metastatic prostate cancer', Expert Review of Anticancer Therapy, vol. 17, no. 11, pp. 1013-1031. https://doi.org/10.1080/14737140.2017.1374858
Dell’Oglio P, Stabile A, Gandaglia G, Zaffuto E, Fossati N, Bandini M et al. New surgical approaches for clinically high-risk or metastatic prostate cancer. Expert Review of Anticancer Therapy. 2017;17(11):1013-1031. https://doi.org/10.1080/14737140.2017.1374858
Dell’Oglio, Paolo ; Stabile, Armando ; Gandaglia, G ; Zaffuto, E ; Fossati, Nicola ; Bandini, M ; Suardi, N ; Karakiewicz, PI ; Shariat, SF ; Montorsi, F ; Briganti, A. / New surgical approaches for clinically high-risk or metastatic prostate cancer. In: Expert Review of Anticancer Therapy. 2017 ; Vol. 17, No. 11. pp. 1013-1031.
@article{a85083663395407fa4a79f5d52c59bcf,
title = "New surgical approaches for clinically high-risk or metastatic prostate cancer",
abstract = "{\circledC} 2017 Informa UK Limited, trading as Taylor & Francis Group. Introduction: A considerable number of individuals with prostate cancer (PCa) still harbor locally-advanced and metastatic disease. Although such men were initially not considered eligible for local treatment, the role of radical prostatectomy (RP) has been recently reassessed. Areas covered: This review analyses currently published evidences regarding new surgical approaches for clinically high-risk PCa individuals, as well as the role of cytoreductive surgery in the metastatic setting. The role of robot-assisted radical prostatectomy (RARP) and extended pelvic lymph node dissection will be evaluated with regards to perioperative, oncologic, as well as functional outcomes. Expert commentary: RARP is a feasible approach in PCa patients regardless of the presence of high-risk disease features and can achieve optimal short-term oncologic outcomes and acceptable short/intermediate-term functional outcomes, that are comparable to those reported for open RP. Extended pelvic lymph node dissection can be performed in this setting and should be recommended for all high-risk PCa patients. The overall rate of complications in contemporary men treated with RARP for high-risk disease is not negligible. Cytoreduction in the oligo-metastatic setting is feasible and relatively safe, although evidence is scarce to recommend its widespread adoption. In consequence, longer follow-up data and, ideally, randomized controlled trials are needed. {\circledC} 2017 Informa UK Limited, trading as Taylor & Francis Group.",
author = "Paolo Dell’Oglio and Armando Stabile and G Gandaglia and E Zaffuto and Nicola Fossati and M Bandini and N Suardi and PI Karakiewicz and SF Shariat and F Montorsi and A Briganti",
year = "2017",
doi = "10.1080/14737140.2017.1374858",
language = "English",
volume = "17",
pages = "1013--1031",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - New surgical approaches for clinically high-risk or metastatic prostate cancer

AU - Dell’Oglio, Paolo

AU - Stabile, Armando

AU - Gandaglia, G

AU - Zaffuto, E

AU - Fossati, Nicola

AU - Bandini, M

AU - Suardi, N

AU - Karakiewicz, PI

AU - Shariat, SF

AU - Montorsi, F

AU - Briganti, A

PY - 2017

Y1 - 2017

N2 - © 2017 Informa UK Limited, trading as Taylor & Francis Group. Introduction: A considerable number of individuals with prostate cancer (PCa) still harbor locally-advanced and metastatic disease. Although such men were initially not considered eligible for local treatment, the role of radical prostatectomy (RP) has been recently reassessed. Areas covered: This review analyses currently published evidences regarding new surgical approaches for clinically high-risk PCa individuals, as well as the role of cytoreductive surgery in the metastatic setting. The role of robot-assisted radical prostatectomy (RARP) and extended pelvic lymph node dissection will be evaluated with regards to perioperative, oncologic, as well as functional outcomes. Expert commentary: RARP is a feasible approach in PCa patients regardless of the presence of high-risk disease features and can achieve optimal short-term oncologic outcomes and acceptable short/intermediate-term functional outcomes, that are comparable to those reported for open RP. Extended pelvic lymph node dissection can be performed in this setting and should be recommended for all high-risk PCa patients. The overall rate of complications in contemporary men treated with RARP for high-risk disease is not negligible. Cytoreduction in the oligo-metastatic setting is feasible and relatively safe, although evidence is scarce to recommend its widespread adoption. In consequence, longer follow-up data and, ideally, randomized controlled trials are needed. © 2017 Informa UK Limited, trading as Taylor & Francis Group.

AB - © 2017 Informa UK Limited, trading as Taylor & Francis Group. Introduction: A considerable number of individuals with prostate cancer (PCa) still harbor locally-advanced and metastatic disease. Although such men were initially not considered eligible for local treatment, the role of radical prostatectomy (RP) has been recently reassessed. Areas covered: This review analyses currently published evidences regarding new surgical approaches for clinically high-risk PCa individuals, as well as the role of cytoreductive surgery in the metastatic setting. The role of robot-assisted radical prostatectomy (RARP) and extended pelvic lymph node dissection will be evaluated with regards to perioperative, oncologic, as well as functional outcomes. Expert commentary: RARP is a feasible approach in PCa patients regardless of the presence of high-risk disease features and can achieve optimal short-term oncologic outcomes and acceptable short/intermediate-term functional outcomes, that are comparable to those reported for open RP. Extended pelvic lymph node dissection can be performed in this setting and should be recommended for all high-risk PCa patients. The overall rate of complications in contemporary men treated with RARP for high-risk disease is not negligible. Cytoreduction in the oligo-metastatic setting is feasible and relatively safe, although evidence is scarce to recommend its widespread adoption. In consequence, longer follow-up data and, ideally, randomized controlled trials are needed. © 2017 Informa UK Limited, trading as Taylor & Francis Group.

U2 - 10.1080/14737140.2017.1374858

DO - 10.1080/14737140.2017.1374858

M3 - Article

VL - 17

SP - 1013

EP - 1031

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 11

ER -